BioCentury | Dec 9, 2020
Deals

Reneo to start pivotal trial in mitochondrial diseases, build orphan pipeline with Novo, Abingworth-led $95M series B

...new CEO to move forward with a potentially pivotal trial in an orphan mitochondrial disorder, Reneo...
...coincides with Reneo’s intent to become a commercially-oriented company that intends to go public.He said Reneo...
...meantime, Reneo expects to start building its commercial infrastructure.Flesher declined to give specific details on Reneo’s...
BioCentury | Oct 17, 2020
Management Tracks

Merck KGaA’s Rossetti retires; plus moves at J&J, Innovent, eFFECTOR, Nautilus, Epirium and more

...as CFO and appointed Sandy Mahatme to the board. Casdin is founder and previous CEO of Reneo...
BioCentury | Apr 28, 2020
Finance

Arch, Cormorant return to lead $200M megaround for Erasca

...closed a $22 million series A extension in March 2019 from Arch, Andreessen Horowitz and Reneo...
BioCentury | Nov 25, 2019
Clinical News

Months after NASH failure, more woes for CymaBay's lead product on safety

...focused on patient follow-up. At least two other companies have PPARδ-targeting products in clinical development. Reneo Pharmaceuticals Inc....
BioCentury | May 20, 2019
Emerging Company Profile

Reneo: Small molecules for rare mitochondrial diseases

...A led by NEA and a management team guided by veterans of Shire takeout Lumena, Reneo...
...its small molecule could carve out a niche in the rare genetic mitochondrial diseases space. Reneo Pharmaceuticals Inc....
...and primary mitochondrial myopathy (PMM). Data from the trials are expected in 1Q20, according to Reneo...
BioCentury | Mar 8, 2019
Financial News

Erasca extends series A by $22M

...total to $64 million. The extension included new investors Arch Venture Partners, Andreessen Horowitz and Reneo...
Items per page:
1 - 6 of 6
BioCentury | Dec 9, 2020
Deals

Reneo to start pivotal trial in mitochondrial diseases, build orphan pipeline with Novo, Abingworth-led $95M series B

...new CEO to move forward with a potentially pivotal trial in an orphan mitochondrial disorder, Reneo...
...coincides with Reneo’s intent to become a commercially-oriented company that intends to go public.He said Reneo...
...meantime, Reneo expects to start building its commercial infrastructure.Flesher declined to give specific details on Reneo’s...
BioCentury | Oct 17, 2020
Management Tracks

Merck KGaA’s Rossetti retires; plus moves at J&J, Innovent, eFFECTOR, Nautilus, Epirium and more

...as CFO and appointed Sandy Mahatme to the board. Casdin is founder and previous CEO of Reneo...
BioCentury | Apr 28, 2020
Finance

Arch, Cormorant return to lead $200M megaround for Erasca

...closed a $22 million series A extension in March 2019 from Arch, Andreessen Horowitz and Reneo...
BioCentury | Nov 25, 2019
Clinical News

Months after NASH failure, more woes for CymaBay's lead product on safety

...focused on patient follow-up. At least two other companies have PPARδ-targeting products in clinical development. Reneo Pharmaceuticals Inc....
BioCentury | May 20, 2019
Emerging Company Profile

Reneo: Small molecules for rare mitochondrial diseases

...A led by NEA and a management team guided by veterans of Shire takeout Lumena, Reneo...
...its small molecule could carve out a niche in the rare genetic mitochondrial diseases space. Reneo Pharmaceuticals Inc....
...and primary mitochondrial myopathy (PMM). Data from the trials are expected in 1Q20, according to Reneo...
BioCentury | Mar 8, 2019
Financial News

Erasca extends series A by $22M

...total to $64 million. The extension included new investors Arch Venture Partners, Andreessen Horowitz and Reneo...
Items per page:
1 - 6 of 6